2015
An analysis of moderators in the COMBINE study: Identifying subgroups of patients who benefit from acamprosate
Gueorguieva R, Wu R, Tsai WM, O’Connor P, Fucito L, Zhang H, O’Malley S. An analysis of moderators in the COMBINE study: Identifying subgroups of patients who benefit from acamprosate. European Neuropsychopharmacology 2015, 25: 1586-1599. PMID: 26141511, PMCID: PMC4600651, DOI: 10.1016/j.euroneuro.2015.06.006.Peer-Reviewed Original ResearchConceptsAcamprosate effectHeavy drinkingShort abstinenceEnhanced treatment responseMonths of treatmentSubgroup of patientsBody mass indexDrug plasma levelsIdentification of subgroupsBetter prognosisLower BMIMass indexPlasma levelsGlutamatergic hyperactivityTreatment responseAcamprosateCOMBINE StudyPrior treatmentLarger studyConsecutive daysAbstinencePretreatment abstinenceTreatment effectsCognitive inefficiencySubgroups
2014
Predictors of Abstinence from Heavy Drinking During Treatment in COMBINE and External Validation in PREDICT
Gueorguieva R, Wu R, O'Connor PG, Weisner C, Fucito LM, Hoffmann S, Mann K, O'Malley SS. Predictors of Abstinence from Heavy Drinking During Treatment in COMBINE and External Validation in PREDICT. Alcohol Clinical And Experimental Research 2014, 38: 2647-2656. PMID: 25346505, PMCID: PMC4397985, DOI: 10.1111/acer.12541.Peer-Reviewed Original ResearchAcamprosateAge FactorsAlcohol AbstinenceAlcohol DeterrentsAlcohol DrinkingBehavior TherapyCombined Modality TherapyControlled Clinical Trials as TopicDecision TreesGamma-GlutamyltransferaseGermanyGoalsHumansLogistic ModelsMiddle AgedNaltrexonePredictive Value of TestsRandomized Controlled Trials as TopicReproducibility of ResultsTaurineTime FactorsTreatment OutcomeUnited States